Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics

Biochemical Pharmacology

Volumn 54, Issue 6, 1997, Pages 685-693

  Melo, Tricia ^a,c   Annie Hua, H ^b   Ballinger, James R ^b   Rauth, Andrew M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

2 Nitroimidazole; Bioreductive; BMS181321; CHO cells; Diagnosis; Hypoxia

Indexed keywords

ETANIDAZOLE; METRONIDAZOLE; MISONIDAZOLE; NF 167; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RP 8979; TINIDAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG INTERACTION; ELECTRON TRANSPORT; HYPOXIA; NONHUMAN; PRIORITY JOURNAL;

EID: 0343488583     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00222-0     Document Type: Article

References (26)

1. Overgaard J, Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6: 509-518, 1994.
2. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26: 45-50, 1993.
3. Stone HB, Brown JM, Phillips TL and Sutherland RM, Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Radiat Res 136: 422-434, 1993.
4. Chapman JD, Hypoxic sensitizers - Implications for radiation therapy. N Engl J Med 301: 1429-1432, 1979.
5. 3H-misonidazole to solid tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 12: 1263-1267, 1986.
6. Koh W-J, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA and Griffin TW, Imaging of hypoxia in tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22: 199-212, 1992.
7. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD and Wiebe LI, Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): A novel marker of tissue hypoxia. J Nucl Med 32: 1764-1770, 1991.
8. Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP and Nunn AD, TcO(PnAO-1-(2-nitroimidazole)) [BMS181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 37: 9-17, 1994.
9. Kusuoka H, Hashimoto K, Fukuchi K and Nishimura T, Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic, and stunned myocardium. J Nucl Med 35: 1371-1376, 1994.
10. DiRocco RJ, Kuczynski BL, Pirro JP, Bauer A, Linder KE, Ramalingam K, Cyr JE, Chan YW, Raju N, Narra RK, Nowotnik DP and Nunn AD, Imaging ischemic tissue at risk of infarction during stroke. J Cereb Blood flow Metab 13: 755-762, 1993.
11. Ballinger JR, Wan Min Kee J and Rauth AM, In vitro and in vivo evaluation of technetium-99m-labelled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 37: 1023-1031, 1996.
12. Koch CJ, Giandomenico AR and Iyengar CWL, Bioreductive metabolism of AF-2 [2-(2-furyl)-3-(5-nitro-furyl)acrytamide] combined with 2-nitroimidazoles. Biochem Pharmacol 46: 1029-1036, 1993.
13. Koch CJ, The reductive activation of nitroimidazoles; Modification by oxygen and other redox-active molecules in cellular systems. In: Selective Activation of Drugs by Redox Processes (Eds. Adams GE, Breccia A, Fielden EM and Wardman P), pp. 237-247-Plenum Press, New York, 1991.
14. Whillans DW and Rauth AM, An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res 84: 97-114, 1980.
15. Taylor YC and Rauth AM, Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res 38: 2745-2752, 1978.
16. Wardman P, Reduction potentials of one-electron couples involving free radicals in aqueous solutions. J Physic Chem Ref Data 18: 1637-1755, 1989.
17. Wardman P, The reduction potential of benzyl viologen: An important reference compound for oxidant/radical redox couples. Free Radic Res Commun 14: 57-67, 1991.
18. Thomson JE and Rauth AM, A comparison of the effectiveness of NF-167 and metronidazole as hypoxic cell sensitizers of KHT tumor cells in vitro. Radiat Res 60: 489-500, 1974.
19. Marshall RS, Koch CJ and Rauth AM, Measurement of low levels of oxygen and their effect on respiration in cell suspensions maintained in an open system. Radiat Res 108: 91-101, 1986.
20. Jayatilak PG, Chan YW, Patel BP, Wen M-L and Rumsey WL, Characterization and subcellular distribution of a novel nitroimidazole complex in the heart. J Nucl Med 35: 152P, 1994.
21. Dische S, Saunders MI, Flockhardt IR, Lee ME and Anderson P, Misonidazole - A drug for trial in radiotherapy and oncology. Int J Radiat Oncol Biol Phys 5: 851-860, 1979.
22. Wasserman TH, Phillips TL, Johnson RJ, Gomer CJ, Lawrence GA, Sadee W, Marques RA, Levin VA and VanRaalte G, Initial United States clinical and pharmacological evaluation of misonidazole (Ro-07-0582), an hypoxic cell radio-sensitizer. Int J Radiat Oncol Biol Phys 5: 775-786, 1979.
23. Olive PL, Enhanced misonidazole binding in the presence of AF-2, Radiat Res 109: 490-499, 1987.
24. Wardman P and Clarke ED, Oxygen inhibition of nitroreductase: Electron transfer from nitro-radical anions to oxygen. Biochem Biophys Res Commun 69: 942-949, 1976.
25. Rauth AM, McClelland RA, Michaels HB and Battistella R, The oxygen dependence of the reduction of nitroimidazoles in a radiolytic model system. Int J Radiat Oncol Biol Phys 10: 1323-1326, 1984.
26. Cowan DSM, Hicks KO and Wilson WR, Diffusion of nitroimidazoles in V79 multicellular membranes, an in vitro model for the extravascular compartment of tumours. Br J Cancer 74 (Suppl 27): S28-S31, 1996.